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Abstract—Interpretability of deep learning (DL) systems is
gaining attention in medical imaging to increase experts’ trust
in the obtained predictions and facilitate their integration in
clinical settings. We propose a deep visualization method to
generate interpretability of DL classification tasks in medical
imaging by means of visual evidence augmentation. The proposed
method iteratively unveils abnormalities based on the prediction
of a classifier trained only with image-level labels. For each
image, initial visual evidence of the prediction is extracted with
a given visual attribution technique. This provides localization of
abnormalities that are then removed through selective inpainting.
We iteratively apply this procedure until the system considers the
image as normal. This yields augmented visual evidence, includ-
ing less discriminative lesions which were not detected at first but
should be considered for final diagnosis. We apply the method to
grading of two retinal diseases in color fundus images: diabetic
retinopathy (DR) and age-related macular degeneration (AMD).
We evaluate the generated visual evidence and the performance of
weakly-supervised localization of different types of DR and AMD
abnormalities, both qualitatively and quantitatively. We show that
the augmented visual evidence of the predictions highlights the
biomarkers considered by the experts for diagnosis and improves
the final localization performance. It results in a relative increase
of 11.2±2.0% per image regarding average sensitivity per average
10 false positives, when applied to different classification tasks,
visual attribution techniques and network architectures. This
makes the proposed method a useful tool for exhaustive visual
support of DL classifiers in medical imaging.
Index Terms—interpretability, deep learning, visualization,
weakly-supervised detection, lesion localization, color fundus
imaging.
I. INTRODUCTION
DEEP learning (DL) systems in medical imaging haveshown to provide high-performing approaches for diverse
classification tasks in healthcare, such as screening of eye
diseases [1], [2], scoring of prostate cancer [3], or detection of
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skin cancer [4]. Nevertheless, DL systems are often referred
to as “black boxes” due to the lack of interpretability of their
predictions. This is problematic in healthcare applications [5],
[6], and hinders experts’ trust and the integration of these
systems in clinical settings as support for grading, diagnosis
and treatment decisions. There is thus an increasing demand
for interpretable systems in medical imaging that could further
explain models’ decisions.
Defining an interpretability framework as the combination
of a DL system to perform a classification task and a procedure
for generating explainable predictions, several such frame-
works have been proposed in different medical applications
and imaging modalities [4], [7]–[17]. Among the integrated
procedures, those based on visual attribution have become very
popular. These attribution methods provide an interpretation of
the network’s decision by assigning an attribution value, some-
times also called ”relevance” or ”contribution”, to each input
feature of the network depending on its estimated contribution
to the network output. [18]. This allows to highlight features
in the input image that contribute to the output prediction; and,
specifically in medical imaging, it allows for the identification
of regions discriminant for the final decision and, conse-
quently, the weakly-supervised localization of abnormalities.
The localized anomalies can provide a clinical explanation of
the classification output without the need for costly lesion-level
annotations.
Classification of disease severity in color fundus (CF)
images, the focus of this paper, is one medical application
where attribution methods have been applied to generate
explainable DL predictions and weakly-supervised detection
of retinal lesions. In [11] and [12], saliency maps [19] were
applied to justify decisions on diabetic retinopathy (DR) and
age-related macular degeneration (AMD) classification tasks,
respectively. In [13], integrated gradients [20] was used to
generate heatmaps for the explanation of predicted DR severity
levels. Class activation maps (CAM) [21] were extracted in
[14] and [15] also for interpretability of DR diagnosis.
Although these interpretability frameworks have succeeded
at localizing abnormal areas related to the predicted diagnosis,
visual attribution based directly on neural network classifiers
has been shown to localize only the most significant regions,
ignoring lesions that have less influence on the classification
result but could be still important for disease understanding
and grading [12], [22]. For some medical imaging modalities
and applications, interpretability of abnormal predictions re-
quires the localization of different types of lesions of varying
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2appearance and histologic composition that can be simultane-
ously present and be responsible for the predicted diagnosis.
To overcome this, in [11] and [12] different classifiers are
used in parallel, which yields localization of different types of
abnormalities in separate maps. This allows for differentiation
of abnormalities, but each input image must be processed sev-
eral times and the interpretability of the actual disease grading
remains unclear. Alternatively, to improve lesion localization,
some frameworks add customized postprocessing steps [11]
or fine-tuning [15] to the attribution methods; or propose
tailored architectures with additional interpretation modules
[16], [17]. Nevertheless, this conflicts with directly obtaining
interpretability of the DL system and hinders the adaptability
and generalization among DL classifiers and medical applica-
tions.
In this paper, we propose a novel deep visualization method,
as an extension to [23], that iteratively unveils abnormalities
responsible for anomalous predictions in order to generate
a map of augmented visual evidence. At each iteration, the
method guides the attention to less discriminative areas that
might also be relevant for the final diagnosis, locating ab-
normalities of different types, shapes and sizes. Defined as a
general approach, it is meant to be seamlessly integrated in
diverse interpretability frameworks with different DL classi-
fiers and visual attribution techniques, and without the need
of additional customized steps.
We apply the proposed method for the interpretation of
automated grading in CF images of two retinal diseases: DR
and AMD [24], [25]. For each diagnosis task, we classify
images by disease severity and analyze the interpretability per-
formance when the proposed iterative augmentation is applied.
We validate the initial and augmented visual evidence maps
qualitatively and, in contrast to most previous approaches, we
evaluate the performance for weakly-supervised localization
of DR and AMD abnormalities quantitatively. We show that
the method can be integrated with different visual attribution
techniques and different DL classifiers.
II. METHODS
The first part of this section describes the proposed iterative
visual evidence augmentation, depicted in Fig. 1. The proposed
method iteratively unveils areas relevant for a final diagnosis,
so as to generate exhaustive visual evidence of classifica-
tion predictions and, consequently, weakly-supervised lesion-
level localization. The second part of the section describes
the image-level classification used to provide the DL-based
decisions to be interpreted.
A. Iterative visual evidence augmentation
Let I ∈ Rm×n×3 be an image with size m × n pix-
els (and 3 color channels) and a corresponding label y,
Fcnn : I −→ yˆ ∈ R a convolutional neural network (CNN)
optimized for a classification task using a development set
I = {(I1, y1), ..., (Is, ys)}, and A : (Rm×n×3,Fcnn) −→
M ∈ Rm×n an attribution method, such as the ones defined
in Table I. For a given I, a prediction yˆ is obtained with
Fcnn. If the image is considered abnormal (or referable in
the case of retinal images), an explanation map M is generated
by applying A, highlighting areas of I that are discriminant
for yˆ. The explanation map M is binarized to identify the
areas where selective inpainting is then applied, in order to
remove abnormalities that have been already localized. This
procedure is applied iteratively to increase attention to less
discriminative areas and generate an augmented explanation
mapM, by increasing the normality of the input image in each
iteration. Algorithm 1 includes the pseudocode to calculate the
augmented visual evidence, and Fig. 1 shows an overview of
the proposed method.
In this work, normality is defined based on the predicted
value yˆ = Fcnn(I), such that an image is considered normal
(or non-referable in the case of retinal images) if yˆ < thpred.
The prediction threshold thpred is defined in a validation
subset of I by means of Receiver Operating Characteristic
(ROC) analysis. The maximum number of iterations T was
set to 20. Regarding binarization of the explanation maps,
we use the Otsu method [26] to compute thbin and yield
an adaptative thresholding. For selective inpainting, we use
the Navier-Stokes method [27] with a radius rinp of size 3,
based on fluid dynamics to match gradient vectors around the
boundaries of the region to be inpainted. The final augmented
explanation map M is obtained by an exponentially decaying
weighted sum of the iteratively generated maps M, with
α = 0.6.
Algorithm 1 Iterative visual evidence augmentation
1: Input: Input image I
2: Trained CNN classifier Fcnn
3: Prediction threshold thpred
4: Maximum number of iterations T
5: Selective inpainting radius rinp
6: Output: Augmented explanation map M
7: Initialize t = 1 and It = I
8: Calculate initial prediction yˆ = Fcnn(It)
9: while (yˆ ≥ thpred) & (t < T ) do
10: Mt = A(It,Fcnn)
11: Binarize Mt by thresholding:
Bt(x, y) =
{
1, if Mt(x, y) ≥ thbin,
0, otherwise
12: Inpaint It given mask Bt:
It = Selective inpainting(It,Bt, rinp)
13: Calculate new prediction yˆ = Fcnn(It)
14: t = t+ 1
15: end while
16: Compute augmented explanation map M:
M =∑t e−αtMt
B. Image-level classification
The proposed iterative visual evidence augmentation must
be built upon a DL classifier that reaches acceptable perfor-
mance, so as to achieve reliable interpretability. Fcnn was
3Fig. 1. Overview of the proposed method applied to automated grading of diabetic retinopathy in color fundus images. The workflow to generate the original
prediction is depicted in green; the workflow for the proposed iterative visual evidence augmentation is depicted in blue.
TABLE I
IMPLEMENTED VISUAL ATTRIBUTION METHODS
Name Definition Description
Saliency [19] MSAL =
∂Fcnn(I)
∂I
It indicates which local morphology changes in the image would lead to modifica-
tions in the network’s prediction.
Guided backpropagation [28]
MGBP =
∂Fcnn(I)
∂I s.t. R
l
i = 1Rl+1i >0
1f li>0R
l+1
i ,
where Rl+1i =
∂Fcnn(I)
∂f l+1i
, f l+1i = ReLU(f
l
i ) and f
l
i is
the i-th feature map at convolutional layer l
It provides additional guidance to the signal backpropagated through ReLU activa-
tions from the higher layers, preventing backward stream of gradients associated to
neurons that decrease the activation of the output node.
Integrated gradients [20] MIG = (I − I¯)
∫ 1
0
∂Fcnn(I¯+α(I−I¯))
∂I dα
The generated maps measure the contribution of each pixel in the input image to the
prediction. Instead of computing only the gradient with respect to the current input
value, this method computes the average gradient while the input varies linearly in
several steps from a baseline image (commonly, all zeros) to their current value.
Grad-CAM [29]
MG−CAM = ReLU(
∑
i α
l
if
l
i ),
where αli = GAP (
∂Fcnn(I)
∂f li
), f li is the i-th feature map
at convolutional layer l and GAP is the global average
pooling operation over the two spatial dimensions
The gradients backpropagated from the output to a selected convolutional layer are
used for computing a linear combination of the forward activation maps of that
layer. Only the pixels with positive influence on the output are maintained, and then
rescaled to the input size.
Guided Grad-CAM [29] MGG−CAM = MG−CAMMGBP
It combines guided backpropagation and Grad-CAM, in order to improve the
localization ability of the latter method.
therefore optimized for each classification task: classification
of CF images for detection of DR (FDRcnn) and AMD (FAMDcnn ).
Prior to classification, every CF image goes through a
preprocessing stage, where the bounding box of the field of
view is extracted, then rescaled to 512 × 512 pixels, and
lastly, contrast-enhancement based on [30] is applied to reduce
local differences in lighting and among images. The contrast-
enhanced image is used as input for the classifier.
The CNNs were based on the VGG-16 architecture [31],
pre-trained on ImageNet. They were adapted to input images
of size 512 × 512 by applying a stride of 2 in the first layer
of the first convolutional block, and using a valid instead of
padded convolution for the first layer of the last convolutional
block. Dropout layers (p=0.5) were added in between the fully-
connected layers. We followed a regression approach in which
the output of a network consists of a single node, representing
a continuous value which is monotonically related to predicted
disease severity. The loss was defined as the mean squared
error between the prediction and the reference-standard label.
For each classification task, the optimal classifier Fcnn was se-
lected regarding the performance on a validation set by means
of receiver operating characteristic (ROC) analysis, computing
the area under the ROC curve (AUC), in order to assure good
discrimination between referable and non-referable cases. Ad-
ditionally, the ability to discriminate between disease stages
was measured by means of the quadratic Cohen’s weighted
kappa coefficient (κ) [32]. Sensitivity (SE) and specificity (SP)
were computed at the optimal operating point of the system,
which was considered to be the best tradeoff between the two
values, i.e., the point closest to the upper left corner of the
graph. This allowed for extraction of the optimal threshold
thpred for referability in the corresponding validation set.
III. DATA
A. Image-level classification
The Kaggle DR dataset [33] was used for training, valida-
tion and testing of FDRcnn . Images were acquired by different
CF digital cameras with varying resolution. Each image was
graded by DR severity by a human reader, regarding the Inter-
national Clinical Diabetic Retinopathy (ICDR) severity scale
[34], with stages 0 (no DR), 1 (mild non-proliferative DR),
2 (moderate non-proliferative DR), 3 (severe non-proliferative
DR), and 4 (proliferative DR). Categories 0 and 1 are con-
sidered non-referable DR and categories 2 to 4 referable DR.
This database is divided in two sets: the Kaggle training set
(35,126 images from 17,563 patients; one photograph per eye)
and the Kaggle test set (53,576 images from 26,788 patients;
one photograph per eye).
4The classifier for AMD, FAMDcnn , was trained, validated and
tested on the Age-Related Eye Disease Study (AREDS) dataset
[35]. AREDS was designed as a long-term prospective study
of AMD development and cataract in which patients were
examined on a regular basis and followed up to 12 years.
The AREDS dbGaP set includes digitalized CF images. In
2014, over 134,000 macula-centered CF images from 4,613
participants were added to the set (for each patient-visit
available, one photograph per eye with their corresponding
stereo pairs). We excluded images regarding the criteria in
the AREDS dbGaP guidelines [35], and 133,820 images were
used in this study. We adapted the grading in AREDS dbGaP,
which is based on the AREDS severity scale for AMD [36],
for reference grading: stage 0 (no AMD), 1 (early AMD), 2
(intermediate AMD), and 3 (advanced AMD, with presence of
foveal geographic atrophy (GA) or choroidal neovasculariza-
tion (CNV)). Categories 0 and 1 are considered non-referable
AMD; categories 2 and 3, referable AMD.
B. Interpretability and weakly-supervised lesion-level detec-
tion with iterative visual evidence augmentation
DiaretDB1 [37] was used for the assessment of the inter-
pretability and weakly-supervised detection of DR abnormal-
ities. This dataset consists of 89 CF images with manually-
delineated areas performed by four medical experts. Four
different types of DR lesions were annotated: hemorrhages,
microaneurysms, hard exudates and soft exudates. As proposed
in [37], we defined the reference standard as binary masks
containing areas labelled with an average confidence level of
75% between experts.
For the assessment of the localization of AMD lesions,
we used CF images from the European Genetic Database
(EUGENDA), a large multi-center database for clinical and
molecular analysis of AMD [38]. AMD severity is defined for
each image according to the Cologne Image Reading Center
and Laboratory (CIRCL) protocol [38]. We generated a dataset
divided in two groups. The first group consists of 52 images
with non-advanced AMD stages [39]. Two trained graders
manually outlined all visible drusen (without sub-dividing
types) in each image, and the binary masks generated during
consensus were used as reference standard. In order to assess
lesion detection in advanced AMD cases, we created a second
group with 12 images with advanced AMD (6 images with
advanced dry AMD and 6 images with advanced wet AMD).
One professional grader manually delineated in each image all
visible AMD-related lesions. To define the reference standard,
we generated two binary masks for each image in this group:
drusen (including hard, soft distinct, soft indistinct and optic
disk drusen) and advanced-AMD lesions (including CNV,
GA and subretinal hemorrhages). In total, 64 images with
manually-annotated abnormalities constituted our EUGENDA
dataset.
IV. EXPERIMENTAL SETUP
A. Image-level classification
The DR classifier FDRcnn was trained on the 80% of the
Kaggle training set (28,098 images) and validated on the
remaining 20% (7,028 images) for 400 epochs. Regarding
training configuration, we used the Adam optimizer [40] with a
learning rate of 0.0001; data augmentation and class balancing
were applied during the training phase to reduce overfitting.
In order to assess the integration of the proposed iterative
visual evidence augmentation with different classification net-
work architectures, we performed an additional validation with
the Inception-v3 architecture [41] for the classification task of
DR grading. As for this alternative DR classifier, FDRcnn,iv3,
a dropout layer (p=0.5) was placed between the final global
average pooling layer and the regression node, and it was
trained for 100 epochs with the training configuration used
previously.
For AMD classification, we applied five-fold cross-
validation: the 4,613 patients in the AREDS dataset were
randomly divided in five groups, and all the images of each
patient were included in the corresponding group. Each fold
had an average number of 26,764 images. Three folds were
used for training, one for validation and one for testing, with
rotation of the folds. In total, five different classifiers were
trained for 80 epochs each, using the previously mentioned
training configuration. We selected as FAMDcnn the model which
yielded best performance on its corresponding test fold.
B. Interpretability and weakly-supervised lesion-level detec-
tion with iterative visual evidence augmentation
The images in the DiaretDB1 dataset and in the EUGENDA
dataset were classified for DR and AMD severity, respectively,
with the corresponding image-level classifier. Images whose
disease severity prediction was over thpred were considered
as referable cases and consequently eligible for interpretability
and evaluation of weakly-supervised lesion detection. Sim-
ilarly to [13], visual evidence of non-referable predictions
does not provide meaningful information, since the proposed
augmentation aims to unveil iteratively abnormalities while the
prediction decreases until non-referability is reached.
The binary masks with annotated lesions were used to
assess if the obtained visual evidence highlighted actual ab-
normalities, and to compare between initial and augmented
visual evidence. Free-response ROC (FROC) curves were used
as evaluation metric of weakly-supervised lesion localization
in each dataset and obtained as follows: the points in the
interpretability maps with highest confidence values were
iteratively located and a circular area of detection with radius r
was defined around. If this area overlapped with any annotated
lesion in the reference standard, that lesion was considered a
true positive detection; otherwise, a false positive detection.
The values of the map within the detection area were then
masked out, and each lesion in the reference standard detected
as true positive was considered only once. For the localization
of DR lesions, we defined r = 7px (1.4% image dimensions);
for AMD, r = 10px (1.9% image dimensions). From the
curves, we extracted values of average sensitivity per average
of 10 false positives per image (SE/10 FPs).
In order to analyze the adaptability of the proposed iter-
ative augmentation to different interpretability methods, we
implemented different visual attribution techniques, included
5in Table I: saliency [19], guided backpropagation [28], in-
tegrated gradients [20], Grad-CAM [29], and Guided Grad-
CAM [29]. Regarding Grad-CAM, due to the extremely coarse
maps generated by this method when the gradient information
from the last convolutional layer is used [29], we used the
information from a shallower convolutional layer (when using
VGG-16: the output of the the third block’s last convolutional
layer (Block 3 conv 3); when using Inception-v3: the output
of the second Inception reduction module (Mixed 8)).
V. RESULTS
A. Image-level classification
The DR classifier FDRcnn obtained an AUC of 0.93, with
a SE of 0.86 and SP of 0.88, on the Kaggle test set. The
model achieved a κ of 0.77 for discrimination between DR
stages. For the alternative classifier based on the Inception-v3
architecture, FDRcnn,iv3, AUC on the Kaggle test set was 0.93,
SE and SP were 0.86 and 0.90, respectively, and κ was 0.80.1
Regarding AMD classification, the overall performance in
the AREDS dataset corresponded to an AUC of 0.97, with SE
of 0.91 and SP of 0.92 at the optimal operating point; κ was
0.87. The model with best performance on the corresponding
test fold and selected as FAMDcnn obtained an AUC of 0.97,
with SE of 0.92 and SP of 0.93, and a κ of 0.88.2
B. Interpretability and weakly-supervised lesion-level detec-
tion with iterative visual evidence augmentation
FDRcnn considered 75 images of the DiaretDB1 to have
referable DR. Initial and augmented visual evidence were
extracted for these cases. Fig. 2 shows one example from the
DiaretDB1 set with the initial and augmented maps for all
the implemented visual attribution methods. Table II includes
the quantitative assessment of weakly-supervised localization
of four types of DR lesions (hemorrhages, microaneurysms,
hard and soft exudates) for the different methods. It contains
the SE/10 FPs values for each type of DR lesion, compar-
ing between initial and augmented visual evidence.3 Fig. 3
illustrates the FROC curves for the initial and augmented
visual evidence per type of lesion generated with guided
backpropagation, which is the method that reached the highest
average performance, as observed in Table V.
When FDRcnn,iv3 was used as DR classifier, 67 images in
the DiaretDB1 dataset were graded as referable DR. The
quantitative results of weakly-supervised detection per DR
lesion for the different visual evidence methods can be found
in Table III, with and without iterative augmentation.
FAMDcnn graded 40 images in the EUGENDA set as referable
AMD. Visual interpretability was extracted for these cases.
Fig. 4 includes one example for qualitative evaluation of
weakly-supervised AMD lesion localization in this set for
1The ROC analyses of the DR classifiers can be found in Fig. S1 (available
in the supplementary files/multimedia tab).
2The ROC analysis on the whole AREDS set, the ROC analysis of the
optimal model, and the performance for each individual model can be found in
Fig. S2, Fig. S3 and Table SI (available in the supplementary files/multimedia
tab).
3An additional example from DiaretDB1 for qualitative assessment can be
found in Fig. S4 (available in the supplementary files/multimedia tab).
all the implemented visual attribution methods, showing the
initial and final visual evidence after iterative augmentation.
The quantitative assessment of localization of drusen and
advanced-AMD lesions can be found in Table IV. In order
to analyze the influence of the advanced AMD cases in lesion
localization performance, separate quantitative evaluation was
carried out on the 52 images with non-advanced AMD stages
in the EUGENDA set and results were also included in Table
IV.4
The global adaptability of the proposed method across
classification tasks, network architectures and visual attribu-
tion methods can be observed in Table V. There is a global
relative increase of 11.2±2.0% per image, in terms of average
sensitivity per average of 10 false positives.
VI. DISCUSSION
Qualitative assessment of the visual evidence generated by
the different implemented interpretability methods shows that
each DL classifier is able to learn visual features relevant
to the classification task at hand during the training process.
For those images classified as referable, most visual features
correspond to actual abnormalities. Augmented visual evi-
dence maps show that the proposed iterative approach allows,
on one hand, to emphasize and achieve better delineations
of detected abnormalities, and, on the other hand, to unveil
abnormalities that were not highlighted at first but are still
related to referable stages and relevant for final diagnosis,
independently of anomaly appearance. This can be especially
observed in severe cases, where the augmented maps differ
more from the initial ones due to a larger number of iterations
needed to reach non-referability.
As observed in Table V, the method can be adapted to
different classification tasks, network architectures and visual
attribution methods. Nevertheless, it can be observed that
iterative augmentation works better when the visual attribution
is not coarse, but well localized. Appropriate spatial resolution
in the initial visual evidence allows to unveil abnormalities of
different types, shapes and sizes, such as the ones related to
retinal diseases. This can be observed when guided backprop-
agation is used for visual attribution. Iterative augmentation
improves localization performance for AMD lesions (Table
IV), as well as for all DR lesions (Table II, Table III, Fig. 3),
where it reaches the highest average performance (Table V).
This corresponds with sharp and localized visual evidence,
as observed in Fig. 2 and Fig. 4. Fig. 5 includes additional
examples for qualitative assessment of weakly-supervised le-
sion detection when this method is applied, highlighting the
importance of good spatial resolution for yielding detailed
visual evidence.
On the other hand, as observed in Fig. 2 and Fig. 4, the maps
generated using Grad-CAM are hardly detailed, even when
a shallower convolutional layer is used for implementation.
This was also reported in [15], where CAM were applied with
specific fine tuning to improve DR lesions localization. Low
spatial resolution prevents these methods from being a suitable
4An additional example from the EUGENDA set for qualitative assessment
can be found in Fig. S5 (available in the supplementary files/multimedia tab).
6TABLE II
AVERAGE SE/10 FPS VALUES FOR WEAKLY-SUPERVISED LESION LOCALIZATION OF DR LESIONS USING VGG-16 ARCHITECTURE.
Grad-CAM Guided Grad-CAM
DR lesion Visual evidence Saliency Guidedbackpropagation
Integrated
gradients Block 3 conv 3 Block 3 conv 3
Initial 0.41 0.65 0.41 0.43 0.66
Hemorrhages Augmented 0.50 0.74 0.58 0.37 0.71
Initial 0.39 0.42 0.29 0.11 0.32
Microaneurysms Augmented 0.33 0.50 0.25 0.11 0.37
Initial 0.32 0.57 0.64 0.43 0.56
Hard exudates Augmented 0.38 0.62 0.63 0.43 0.68
Initial 0.45 0.67 0.83 0.58 0.70
Soft exudates Augmented 0.58 0.93 0.98 0.60 0.90
Evaluation performed in cases classified as referable DR in the DiaretDB1 dataset (75/89 images). Shade indicates higher performance after iterative augmentation;
bold indicates highest performance per lesion type.
Fig. 2. Example of visual evidence generated with different methods for one image of DiaretDB1, predicted as DR stage 3 with the DR classifier based on
VGG-16. For each method: initial visual evidence (left) and augmented visual evidence (right).
TABLE III
AVERAGE SE/10 FPS VALUES FOR WEAKLY-SUPERVISED LESION LOCALIZATION OF DR LESIONS USING INCEPTION-V3 ARCHITECTURE.
Grad-CAM Guided Grad-CAM
DR lesion Visual evidence Saliency Guidedbackpropagation
Integrated
gradients Mixed 8 Mixed 8
Initial 0.24 0.67 0.40 0.07 0.60
Hemorrhages Augmented 0.32 0.76 0.55 0.09 0.64
Initial 0.23 0.55 0.24 0.00 0.50
Microaneurysms Augmented 0.24 0.59 0.22 0.03 0.44
Initial 0.17 0.58 0.71 0.39 0.66
Hard exudates Augmented 0.20 0.62 0.70 0.31 0.65
Initial 0.13 0.50 0.60 0.03 0.57
Soft exudates Augmented 0.23 0.73 0.83 0.03 0.63
Evaluation performed in cases classified as referable DR in the DiaretDB1 dataset (67/89 images). Shade indicates higher performance after iterative augmentation;
bold indicates highest performance per lesion type.
7TABLE IV
AVERAGE SE/10 FPS VALUES FOR WEAKLY-SUPERVISED LESION LOCALIZATION OF AMD LESIONS USING VGG-16 ARCHITECTURE.
Grad-CAM Guided Grad-CAM
DR lesion Visual evidence Saliency Guidedbackpropagation
Integrated
gradients Block 3 conv 3 Block 3 conv 3
All EUGENDA (40/64 classified as referable AMD)
Initial 0.22 0.38 0.37 0.03 0.25
Drusen Augmented 0.26 0.44 0.45 0.02 0.26
Initial 0.92 0.83 0.98 0.27 0.88
Advanced lesions Augmented 0.92 0.89 0.97 0.38 0.88
Non-advanced EUGENDA (28/52 classified as referable AMD)
Initial 0.22 0.42 0.40 0.02 0.27
Drusen Augmented 0.27 0.51 0.50 0.01 0.28
Shade indicates higher performance after iterative augmentation; bold indicates highest performance per lesion type.
TABLE V
AVERAGE LESION LOCALIZATION PERFORMANCE (AVERAGE SE/10 FPS) FOR EACH VALIDATED CLASSIFICATION TASK AND NETWORK ARCHITECTURE.
Classification task
and architecture Visual evidence Saliency
Guided
backpropagation
Integrated
gradients Grad-CAM Guided Grad-CAM
Initial 0.39± 0.05 0.58± 0.10 0.54± 0.21 0.39± 0.17 0.56± 0.15
DR, VGG-16 Augmented 0.45± 0.10 0.70± 0.16 0.61± 0.26 0.38± 0.18 0.67± 0.19
Initial 0.19± 0.04 0.58± 0.06 0.49± 0.18 0.12± 0.16 0.58± 0.06
DR, Inception-v3 Augmented 0.25± 0.04 0.68± 0.07 0.58± 0.23 0.11± 0.11 0.59± 0.09
Initial 0.57± 0.33 0.61± 0.22 0.68± 0.31 0.15± 0.12 0.57± 0.32
AMD, VGG-16 Augmented 0.59± 0.33 0.67± 0.23 0.71± 0.26 0.20± 0.18 0.57± 0.31
Shade indicates higher performance after iterative augmentation; bold indicates highest performance per classification task and architecture.
Fig. 3. Lesion localization performance of initial and augmented visual
evidence per type of lesion in referable DR predictions from the DiaretDB1
dataset, when using the DR classifier based on VGG-16 and guided back-
propagation for visual attribution.
option for interpretability of classification tasks that require
precise lesion localization and, in these cases, augmentation
does not help, as shown also quantitatively in Tables II, III and
IV. Guided Grad-CAM, due to the combination with guided
backpropagation, provides more localized visual evidence and
good detection performance especially for most DR lesions,
although not better than using guided backpropagation alone,
as seen in Table V.
As for saliency maps, which are more localized than
Grad-CAM, augmentation shows visually and quantitatively
improvement for detection of most lesions, although final
sensitivity values are not high. These maps were used in [11],
but adjustment of the training loss and customized, complex
postprocessing steps were required to reduce the inherent
noise.
Integrated gradients yields better general performance than
saliency and Grad-CAM, but maps are more noisy than those
obtained with guided backpropagation. Iterative augmentation
enhances the localization of AMD lesions, reaching the highest
average performance, as seen in Table V, and certain DR
lesions. However, the coarseness and noise of the maps hinders
the augmentation’s performance for extremely small lesions,
such as microaneurysms. Integrated gradients was used in
[13], showing support for DR graders, improving confidence
and time on task, although no quantitative results of lesion
localization were included.
Regarding the adaptability of the proposed method to dif-
ferent architectures, the results in Table III show that weakly-
supervised localization of lesions can be generated with differ-
ent and deeper networks, such as Inception-v3, and improved
by means of iterative augmentation.
To the extent of our knowledge, we provide the first quan-
titative evaluation of weakly-supervised localization of AMD
lesions in CF images. As observed in Table IV, advanced-
AMD lesions, which should never be missed in grading set-
tings, are fast and intensely detected with most interpretability
techniques. Augmentation improves drusen detection, although
general performance is lower than for DR lesions. This might
be related to different aspects. On one hand, AMD grading and
annotation of related lesions pose several difficulties to human
experts [42], which transfers to the training of DL systems.
On the other hand, there is a wide variety of drusen types
[43] that are grouped in the presented validation. Table IV
illustrates improvement in drusen detection when advanced
cases are excluded, i.e., drusen present in advanced AMD
stages are harder to unveil, as well as harder for experts
to grade [42]. Interpretability of AMD detection will benefit
from a validation with further differentiation of drusen types.
This would help identify classification burdens and consequent
aspects for training optimization.
We used an unsupervised inpainting technique [27] which
8Fig. 4. Example of visual evidence generated with different methods for one image of EUGENDA, predicted as AMD stage 2 (ground-truth label: AMD
stage 2). For each method: initial visual evidence (left) and augmented visual evidence (right).
yielded satisfactory visual results and fast processing times
during iterative augmentation. Future work might include more
advanced inpainting techniques, at pixel-level or patch-level,
or also trainable with healthy images, such as generative
models [44] or context encoders [45].
There are other methods for visual evidence that we have
not implemented but that might be interesting to consider for
future comparison and integration of iterative augmentation.
For instance, layer-wise relevance propagation and its variants
[46], [47]. They can be directly applied to a trained classifier
to extract interpretability of the predictions and might benefit
from iterative augmentation.
Although the proposed method allows to generate an aug-
mented map of visual evidence agnostic to anomaly type and
appearance for each prediction, differentiation among detected
abnormalities can be useful for a complete explainable diagno-
sis. In [12], saliency maps were extracted from three different
AMD-related classifiers (presence of late-AMD, drusen, and
pigmentary abnormalities), yielding one interpretability map
per classification task. An ensemble of classifiers for DR
grading was used in [11], where one model provided the
final DR grade and other models were optimized to provide
a map for a given DR lesion type. These solutions allow for
separate and optimized interpretability of predictions related to
disease grading with respect to a certain lesion type. However,
each input image must be processed several times and with
multiple maps there is no global and direct interpretation of
the actual disease classification. In the future, interpretability
of a given classification task will benefit from using the
knowledge contained in the corresponding trained network
also for differentiation of the lesions included in the visual
evidence maps.
The integration of other techniques might improve the
usability of the proposed method and help increase trust in
the output of the DL classifiers where applied. For example,
quantifying and providing information about the uncertainty of
the system’s decisions [48], or exploiting the features learned
by the system not only for visual evidence of decisions but
also for semantic interpretation [49]. This would allow for
better understanding of the features learned by the classifier in
the training process and their impact on the final predictions,
leading to identify different types of lesions and how they
relate to disease severity, as well as new biomarkers significant
for disease diagnosis.
VII. CONCLUSION
We proposed a deep visualization method for exhaustive
visual interpretability of DL classification tasks in medical
imaging. The method allows to iteratively increase attention
to less discriminative areas that should be considered for
final diagnosis, while being adaptable to different classi-
fication tasks, network architectures and visual attribution
9Fig. 5. Examples of visual evidence generated with guided backpropagation for two images in the DiaretDB1 dataset, predicted as DR stage 2 (first row)
and 3 (second row), and for two images in the EUGENDA dataset, predicted as AMD stage 2 (third row; ground-truth label: AMD stage 2) and predicted as
AMD stage 3 (fourth row; ground-truth label: AMD stage 3).
techniques. We showed that visual evidence of the predictions
can achieve weakly-supervised lesion-level detection and in-
clude the biomarkers considered by the experts for diagno-
sis. Augmented visual evidence improves the final detection
performance, being agnostic to anomaly type and appearance
and performing better with sharp and localized initial visual
attribution. This makes the proposed method a useful tool for
supporting the decisions of medical DL-based classification
systems, in order to increase the experts’ trust and facilitate
their final integration in clinical settings.
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